Which company develops and produces entrectinib?

Entrectinib is produced by Swiss Roche Pharmaceuticals (Roche)Developed and produced by the company, entrectinib is an anti-cancer drug used to treat ROS1-positive non-small cell lung cancer and NTRK fusion-positive solid tumors. Entrectinib was approved for medical use in the United States in August 2019, and entrectinib was approved for medical use in the United States in 2020. It was approved for medical use in Australia in May 2020, and entrectinib was approved for medical use in the European Union in July 2020.

The most common side effects of entrectinib include fatigue, constipation, dysgeusia, edema (edema with fluid retention), dizziness, diarrhea, nausea, dysesthesia (unpleasant and unusual feeling when touched), dyspnea (trouble breathing), anemia (low red blood cell count), weight gain, elevated blood creatinine (which may be a sign of kidney problems), pain, cognitive impairment (problems with thinking, learning, and memory), vomiting, cough, and fever.

Entrectinib and its active metabolites inhibit several pathways that contribute to cell survival and proliferation. This inhibition changes the balance in favor of apoptosis, thereby preventing cancer cell growth and shrinking tumors. Avoid grapefruit products, Grapefruit inhibitsCYP3A metabolism, which may increaseserum concentrations of entrectinib. Avoid using St. John's wort. The herb induces CYP3A metabolism and may decrease entrectinib serum levels. There are generic drugs in Laos, the officially marketed version, with government approval, retail price of pharmaceuticals in Laos and ASEAN200mg90tablets20000yuan, 100mg30 tablets6500yuan. If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.